ub.xmlui.mirage2.page-structure.muninLogoub.xmlui.mirage2.page-structure.openResearchArchiveLogo
    • EnglishEnglish
    • norsknorsk
  • Velg spraaknorsk 
    • EnglishEnglish
    • norsknorsk
  • Administrasjon/UB
Vis innførsel 
  •   Hjem
  • Det helsevitenskapelige fakultet
  • Institutt for medisinsk biologi
  • Artikler, rapporter og annet (medisinsk biologi)
  • Vis innførsel
  •   Hjem
  • Det helsevitenskapelige fakultet
  • Institutt for medisinsk biologi
  • Artikler, rapporter og annet (medisinsk biologi)
  • Vis innførsel
JavaScript is disabled for your browser. Some features of this site may not work without it.

Serum levels of inflammation-related markers and metabolites predict response to neoadjuvant chemotherapy with and without bevacizumab in breast cancers

Permanent lenke
https://hdl.handle.net/10037/18340
DOI
https://doi.org/10.1002/ijc.32638
Thumbnail
Åpne
article.pdf (3.312Mb)
Publisert versjon (PDF)
Dato
2019-08-24
Type
Journal article
Tidsskriftartikkel
Peer reviewed

Forfatter
Nome, Marianne Eikhom; Euceda, Leslie R.; Jabeen, Shakila; Debik, Julia; Bathen, Tone Frost; Giskeødegård, Guro F.; Tasken, Kristin Austlid; Mælandsmo, Gunhild Mari; Halvorsen, Bente; Yndestad, Arne; Borgen, Elin; Garred, Øystein; Aukrust, Pål; Ueland, Thor; Engebraaten, Olav; Kristensen, Vessela N.; Tekpli, Xavier
Sammendrag
Angiogenesis is necessary for tumor growth and has been targeted in breast cancer; however, it is unclear which patients will respond and benefit from antiangiogenic therapy. We report noninvasive monitoring of patient response to neoadjuvant chemotherapy given alone or in combination with anti‐vascular endothelial growth factor (bevacizumab) in a randomized clinical trial. At four time points during neoadjuvant chemotherapy ± bevacizumab of receptor tyrosine‐protein kinase erbB‐2‐negative breast cancers, we measured metabolites and inflammation‐related markers in patient's serum. We report significant changes in the levels of several molecules induced by bevacizumab, the most prominent being an increase in pentraxin 3 (PTX3) and von Willebrand factor (VWF). Serum levels of AXL, VWF and pulmonary and activation‐regulated cytokine (PARC/CCL18) reflected response to chemotherapy alone or in combination with bevacizumab. We further analyzed serum cytokines in relation to tumor characteristics such as gene expression, tumor metabolites and tumor infiltrating leukocytes. We found that VWF and growth‐differentiation factor 15 tumor mRNA levels correlated with their respective serum protein levels suggesting that these cytokines may be produced by tumors and outflow to the bloodstream while influencing the tumor microenvironment locally. Finally, we used binomial logistic regression which allowed to predict patient's response using only 10 noninvasive biomarkers. Our study highlights the potential of monitoring circulating levels of cytokines and metabolites during breast cancer therapy.
Forlag
John Wiley ans Sons
Sitering
Nome, M.N., Euceda L.R., Jabeen S, Debik JD, Bathen TF, Giskeødegård G.F., Tasken KA, Mælandsmo GM, Halvorsen BE, Yndestad A, Borgen E, Garred Ø, Aukrust P, Ueland T, Engebraaten O, Kristensen VN, Tekpli X. (2019) Serum levels of inflammation-related markers and metabolites predict response to neoadjuvant chemotherapy with and without bevacizumab in breast cancers. International Journal of Cancer, 2019, 146, 223-235.
Metadata
Vis full innførsel
Samlinger
  • Artikler, rapporter og annet (medisinsk biologi) [1103]
Copyright 2019 The Author(s)

Bla

Bla i hele MuninEnheter og samlingerForfatterlisteTittelDatoBla i denne samlingenForfatterlisteTittelDato
Logg inn

Statistikk

Antall visninger
UiT

Munin bygger på DSpace

UiT Norges Arktiske Universitet
Universitetsbiblioteket
uit.no/ub - munin@ub.uit.no

Tilgjengelighetserklæring